These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 11103803

  • 1. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T, Miyazawa N, Moore MA, Crystal RG.
    Cancer Res; 2000 Nov 15; 60(22):6391-5. PubMed ID: 11103803
    [Abstract] [Full Text] [Related]

  • 2. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A, Butterfield LH, Amarnani SN, Dissette VB, Kim D, Meng WS, Miranda GA, Wang HJ, McBride WH, Glaspy JA, Economou JS.
    Cancer Res; 2001 Dec 15; 61(24):8787-93. PubMed ID: 11751400
    [Abstract] [Full Text] [Related]

  • 3. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M, Andarini S, Zaini J, Xin H, Kanehira M, Suzuki T, Fukuhara T, Mizuguchi H, Hayakawa T, Saijo Y, Nukiwa T, Kikuchi T.
    Eur J Immunol; 2006 Apr 15; 36(4):1019-27. PubMed ID: 16525992
    [Abstract] [Full Text] [Related]

  • 4. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
    Liu Y, Xia D, Li F, Zheng C, Xiang J.
    Cancer Gene Ther; 2005 Feb 15; 12(2):122-32. PubMed ID: 15565183
    [Abstract] [Full Text] [Related]

  • 5. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y, Zhang X, Zhang W, Chen Z, Chan T, Ali K, Jia Z, Xiang J.
    Cancer Gene Ther; 2002 Feb 15; 9(2):202-8. PubMed ID: 11857039
    [Abstract] [Full Text] [Related]

  • 6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 15; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
    Sun Y, Peng D, Lecanda J, Schmitz V, Barajas M, Qian C, Prieto J.
    Gene Ther; 2000 Sep 15; 7(17):1467-76. PubMed ID: 11001366
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL.
    J Immunol; 1999 Jul 15; 163(2):699-707. PubMed ID: 10395660
    [Abstract] [Full Text] [Related]

  • 12. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth.
    Fushimi T, O'Connor TP, Crystal RG.
    Cancer Res; 2006 Apr 01; 66(7):3513-22. PubMed ID: 16585175
    [Abstract] [Full Text] [Related]

  • 13. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W, Tong Y, Carpenter H, Kong HL, Crystal RG.
    Gene Ther; 2000 Dec 01; 7(24):2080-6. PubMed ID: 11223988
    [Abstract] [Full Text] [Related]

  • 14. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector.
    Kimura T, Ohashi T, Kikuchi T, Kiyota H, Eto Y, Ohishi Y.
    Cancer Gene Ther; 2003 Nov 01; 10(11):833-9. PubMed ID: 14605669
    [Abstract] [Full Text] [Related]

  • 15. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
    Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT.
    Cancer Res; 2000 Oct 01; 60(19):5456-63. PubMed ID: 11034088
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P, De Meyer M, Leroy P, Rousseau C, Acres B.
    Cancer Gene Ther; 2001 May 01; 8(5):321-32. PubMed ID: 11477452
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J, Saffold S, Cao X, Krauss J, Chen W.
    J Immunol; 1998 Nov 15; 161(10):5516-24. PubMed ID: 9820528
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.